Israel
|
001-36621
|
N/A
|
|||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|||
|
|
|
|
||
|
2 Holzman Street,
Weizmann Science Park
|
|
|
||
|
Rehovot, Israel
|
7670402
|
|
||
|
(Address of principal executive offices)
|
(Zip Code)
|
|
||
|
|||||
+972-8-9316233
|
|||||
(Registrant’s telephone number, including area code)
|
|||||
(Former name or former address, if changed since last report)
|
Securities registered pursuant to Section 12(b) of the Act:
|
||
Title of each class
|
Ticker symbol(s)
|
Name of each exchange on which registered
|
Ordinary Shares, par value NIS 0.16 per share
|
FOMX
|
Nasdaq Global Stock Market
|
Exhibit No.
|
|
Description
|
|
|
|
|
FOAMIX PHARMACEUTICALS LTD.
|
|
|
|
|
|
By:
|
/s/ Mutya Harsch
|
|
|
Mutya Harsch
|
|
|
Chief Legal Officer
|
Contact:
|
U.S. Investor Relations
|
Ilan Hadar, CFO & Country Manager
|
Joyce Allaire
|
Foamix Pharmaceuticals Ltd.
|
LifeSci Advisors, LLC
|
+972-8-9316233
|
646-889-1200
|
ilan.hadar@foamixpharma.com
|
jallaire@lifesciadvisors.com
|